Is Datopotamab currently officially available globally?

Datopotamab deruxtecan is an innovative antibody-drug conjugate (ADC), mainly used to treat patients with specific types of breast cancer and non-small cell lung cancer (NSCLC). The drug targets specific antigens on the surface of tumor cells through the antibody moiety, and delivers cytotoxic drugs directly into cancer cells, thereby achieving precise killing and reducing damage to normal cells. With its unique mechanism of action, dabrotuzumab shows good potential and efficacy in the field of anti-tumor treatment.

Currently, dabrotuzumab has obtained official marketing authorization in the United States and Europe. 2025At the beginning of 2025, the U.S. Food and Drug Administration (FDA) approved the drug for the treatment of patients with hormone receptor-positive, HER2-negative breast cancer that remains unresectable or metastatic after endocrine therapy and chemotherapy. Subsequently, the FDA further approved the drug for patients with EGFR mutated advanced or metastatic non-small cell lung cancer who have previously received EGFR targeted therapy and platinum-based chemotherapy but whose disease has progressed. The European Medicines Agency (EMA) also granted marketing authorization to the drug in 2025 for the treatment of similar indications.

Although dabrotuzumab has been approved in the European and American markets, it has not yet been approved by the National Food and Drug Administration (NMPA) in mainland China, so patients cannot obtain the drug through formal channels. If Chinese patients want to use dabrotuzumab, they usually need to participate in clinical trials or obtain it through overseas medical channels. As China's drug approval system continues to improve, it is expected that this drug will enter the Chinese market in the future, bringing new treatment options to more patients.

Overall, as a new type of antibody-conjugated drug, dabrotuzumab has gradually entered the clinical application stage around the world, especially in the treatment of breast cancer and non-small cell lung cancer, showing significant efficacy. As more clinical data accumulates and approval progresses, its indications are expected to continue to expand and benefit more patients. During the treatment process, patients should follow the doctor's instructions, arrange medication reasonably, pay attention to drug safety and efficacy, and strive to obtain the best therapeutic effect.

Reference materials:https://www.drugs.com/